Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Type 2 collagen is a major structural protein found in cartilage and is widely used as a dietary supplement and nutraceutical for joint health. In the context of osteoarthritis, it is believed to function through a mechanism known as oral tolerance. When ingested in small amounts, the protein interacts with gut-associated lymphoid tissue (GALT), which helps to desensitize the immune system and suppress the inflammatory T-cell response against endogenous type II collagen in the joints. This modulation helps to reduce joint pain, inflammation, and cartilage degradation. In clinical research sponsored by TCI Co., Ltd., Type 2 collagen has been utilized as a positive control in studies evaluating the efficacy of other interventions, such as the probiotic TCI633, for the treatment of knee osteoarthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Type 2 collagen.